Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

Feature | Dave Fornell

A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to ...

Home April 08, 2011
Home
Feature

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College ...

Home April 06, 2011
Home
News

April 6, 2011 – Results from a pooled patient-level analysis favored a next-generation paclitaxel-eluting stent ...

Home April 06, 2011
Home
Feature

April 6, 2011 – A pooled analysis of the SPIRIT II, III, IV and COMPARE trials further reinforces the positive ...

Home April 06, 2011
Home
News

March 21, 2011 - OrbusNeich today announced it filed a lawsuit in the Netherlands against a doctor and principal ...

Home March 21, 2011
Home
News

February 21, 2011 – Two drug-eluting coronary stent systems have been launched in India. Boston Scientific’s ...

Home February 21, 2011
Home
News

February 21, 2011 – The first patient has been enrolled the DESSOLVE II study to support CE mark for a coronary ...

Home February 21, 2011
Home
News

January 26, 2011 – Patient enrollment has begun in China for a trial evaluating the safety and effectiveness of a ...

Home January 26, 2011
Home
News

January 24, 2011 – Patient enrollment was completed in the EVOLVE clinical trial, which is designed to assess the ...

Home January 24, 2011
Home
News

January 20, 2011 – European CE mark approval was granted to expand the indication of Abbott’s Xience Prime ...

Home January 21, 2011
Home
News

January 20, 2011 – Drug-coated stents hold promise as a safe and lasting solution for the treatment of clogged leg ...

Home October 10, 2011
Home
Feature

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting ...

Home January 10, 2011
Home
News

December 6, 2010 - A European court has struck a blow to Boston Scientific's alleged patent infringement case ...

Home December 06, 2010
Home
News

September 28, 2010 – Three-year follow-up data from the HORIZONS-AMI trial presented at Transcatheter ...

Home September 28, 2010
Home
News

September 24, 2010 – Drug-eluting stents are beneficial in treating symptomatic peripheral artery disease (PAD) in ...

Home September 24, 2010
Home
Subscribe Now